Leonid Timashev
Stock Analyst at RBC Capital
(3.70)
# 739
Out of 5,154 analysts
158
Total ratings
44.68%
Success rate
8.93%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $12 → $13 | $4.59 | +183.22% | 5 | Mar 3, 2026 | |
| BHVN Biohaven | Maintains: Outperform | $22 → $23 | $9.92 | +131.85% | 15 | Mar 3, 2026 | |
| EXEL Exelixis | Maintains: Sector Perform | $46 → $43 | $41.55 | +3.50% | 4 | Mar 2, 2026 | |
| ONC BeOne Medicines AG | Maintains: Outperform | $417 → $425 | $301.12 | +41.14% | 6 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Outperform | $47 → $45 | $28.63 | +57.18% | 6 | Feb 26, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $191 → $195 | $182.01 | +7.14% | 4 | Feb 25, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $219 → $222 | $162.33 | +36.76% | 16 | Feb 24, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $95 → $101 | $60.41 | +67.19% | 7 | Feb 20, 2026 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $49 | $33.19 | +47.63% | 5 | Feb 18, 2026 | |
| CMPS COMPASS Pathways | Maintains: Outperform | $21 → $22 | $6.58 | +234.35% | 6 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $61 → $73 | $61.88 | +17.97% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $29.86 | +57.40% | 9 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $13 | $6.46 | +101.24% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $77 → $140 | $98.40 | +42.28% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $197 → $200 | $140.13 | +42.72% | 8 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 | $18.97 | +247.92% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.37 | +264.96% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $13 | $10.05 | +29.35% | 10 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.38 | +189.86% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $27.82 | +79.73% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $11.32 | +67.84% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $27 → $11 | $5.20 | +111.54% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $6.38 | +103.76% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $4.11 | +21.65% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $4.97 | +221.93% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.78 | +282.46% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $95.94 | -27.04% | 1 | Jan 23, 2025 |
Nuvation Bio
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $4.59
Upside: +183.22%
Biohaven
Mar 3, 2026
Maintains: Outperform
Price Target: $22 → $23
Current: $9.92
Upside: +131.85%
Exelixis
Mar 2, 2026
Maintains: Sector Perform
Price Target: $46 → $43
Current: $41.55
Upside: +3.50%
BeOne Medicines AG
Feb 27, 2026
Maintains: Outperform
Price Target: $417 → $425
Current: $301.12
Upside: +41.14%
Alkermes
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $45
Current: $28.63
Upside: +57.18%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $191 → $195
Current: $182.01
Upside: +7.14%
Axsome Therapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $219 → $222
Current: $162.33
Upside: +36.76%
Cytokinetics
Feb 20, 2026
Maintains: Outperform
Price Target: $95 → $101
Current: $60.41
Upside: +67.19%
IDEAYA Biosciences
Feb 18, 2026
Reiterates: Outperform
Price Target: $49
Current: $33.19
Upside: +47.63%
COMPASS Pathways
Feb 18, 2026
Maintains: Outperform
Price Target: $21 → $22
Current: $6.58
Upside: +234.35%
Jan 21, 2026
Maintains: Outperform
Price Target: $61 → $73
Current: $61.88
Upside: +17.97%
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $29.86
Upside: +57.40%
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $6.46
Upside: +101.24%
Jan 21, 2026
Maintains: Outperform
Price Target: $77 → $140
Current: $98.40
Upside: +42.28%
Jan 21, 2026
Maintains: Outperform
Price Target: $197 → $200
Current: $140.13
Upside: +42.72%
Jan 20, 2026
Maintains: Outperform
Price Target: $66
Current: $18.97
Upside: +247.92%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.37
Upside: +264.96%
Nov 20, 2025
Upgrades: Outperform
Price Target: $6 → $13
Current: $10.05
Upside: +29.35%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.38
Upside: +189.86%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $27.82
Upside: +79.73%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $11.32
Upside: +67.84%
Oct 31, 2025
Downgrades: Sector Perform
Price Target: $27 → $11
Current: $5.20
Upside: +111.54%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $6.38
Upside: +103.76%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $4.11
Upside: +21.65%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $4.97
Upside: +221.93%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $0.78
Upside: +282.46%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $95.94
Upside: -27.04%